Regeneron’s LAG-3 inhibitor fianlimab missed a late-stage mark in melanoma, failing to significantly outperform Keytruda (pembrolizumab) in a Phase 3 setting in untreated patients with unresectable locally advanced or metastatic disease. The readout compounds recent clinical setbacks for the LAG-3 class and intensifies scrutiny of combination strategies in this space. Separate from the clinical disappointment, Regeneron has been pivoting to new platform bets and partnering arrangements, underscoring how quickly late-stage outcomes can reshape capital allocation and pipeline prioritization. For investors and trial teams, the failed endpoint refocuses attention on biomarkers, patient selection, and the durability of benefit in LAG-3-centered approaches.